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Abstract: Purpose: Dry powder vaccine delivery via the pulmonary route has gained significant
attention as an alternate route to parenteral delivery. In this study, we investigated
bovine serum albumin (BSA) adsorbed poly(glycerol adipate-co-ω-pentadecalactone),
PGA-co-PDL polymeric nanoparticles (NPs) within L-leucine (L-leu) microcarriers for
dry powder inhalation.
Methods: NPs were prepared by oil-in-water single emulsion-solvent evaporation and
particle size optimised using Taguchi's design of experiment. BSA was adsorbed onto
NPs at different ratios at room temperature. The NPs were spray-dried in aqueous
suspension of L-leu (1:1.5) using a Büchi-290 mini-spray dryer. The resultant
nanocomposite microparticles (NCMPs) were characterised for toxicity (MTT assay),
aerosolization (Next Generation Impactor), in vitro release study and BSA was
characterized using SDS-PAGE and CD respectively.
Results: NPs of size 128.50±6.57nm, PDI 0.07±0.03 suitable for targeting lung
dendritic cells were produced. BSA adsorption for 1h resulted in 10.23±1.87µg of
protein per mg of NPs. Spray-drying with L-leu resulted in NCMPs with 42.35±3.17%
yield. In vitro release study at 37°C showed an initial burst release of 30.15±2.33% with
95.15±1.08% over 48h. Aerosolization studies indicated fine particle fraction (FPF%)
dae<4.46μm as 76.95±5.61% and mass median aerodynamic diameter (MMAD) of
1.21±0.67µm. The cell viability was 87.01±14.11% (A549 cell line) and 106.04±21.14%
(16HBE14o- cell line) with L-leu based NCMPs at 1.25mg/ml concentration after 24h
treatment. The SDS-PAGE and CD confirmed the primary and secondary structure of
the released BSA.
Conclusion: The results suggest that PGA-co-PDL/L-leu NCMPs may be a promising
carrier for pulmonary vaccine delivery due to excellent BSA adsorption and
aerosolization behaviour.
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Dear Dr Peter Swaan, 
 
My name is Dr Imran Saleem from the School of Pharmacy & Biomolecular Sciences 
at Liverpool John Moores University, UK. I would like to submit my research article for 
consideration of publication in the Pharmaceutical Research journal. Furthermore, I explicitly 
state that the manuscript has not been previously published in any language anywhere and 
that it is not under simultaneous consideration by another journal. 
 
Recent advances in inhalation therapy have provoked considerable interest in the 
development of novel formulations intended for pulmonary delivery of vaccines. The 
delivery of antigens formulated as nanoparticles or nanoparticles within microparticles in a 
dry powder state using dry powder inhalers (DPIs) via the pulmonary route induces both 
mucosal and systemic immunity. The nanoparticulate formulations have greater chance of 
uptake by the immune cells, such as dendritic cells, as they reach effectively to the 
respiratory pathways thus requiring less dosage for achieving vaccination. In this article, we 
used an experimental design to obtain and produce nanoparticles suitable for targeting the 
dendritic cells. The nanoparticles adsorb a model protein, bovine serum albumin, and are 
formulated into nanocomposite microparticles using carriers for an efficient pulmonary 
vaccine delivery.  
I look forward to hearing from you 
Regards 
 
Dr Imran Saleem BSc., MRPharmS, Ph.D, FHEA 
Senior Lecturer Pharmaceutical Technology 
Pharmacy and Biomolecular Sciences 
Liverpool John Moores University 
James Parsons Building, Byrom Street, Liverpool, L3 3AF 
Tel: +44(0)151 231 2265; Fax: +44(0)151 231 2170   
E-mail: I.Saleem@ljmu.ac.uk 
Cover Letter
We would like to thank the reviewer for the valuable suggestions and feedback and we have 
undertaken additional experiments, supplemented with the results and tried to address the concerns. 
Reviewers' comments: 
Reviewer #1: The revised manuscript has made lots of improvements. The authors provided more data 
to show that BSA was adsorbed on the PGA-co-PDL nanocarriers, and the secondary structure of BSA 
released from the naonocarriers was similar to the original one. However, the manuscript only showed 
that these particles can be used for pulmonary delivery of BSA. It is not convincing that these 
nanocarriers are appropriate for vaccine delivery for the following two reasons:  
1) The activity of the PGA-co-PDL nanocarriers was speculated only based on particle sizes. Though 
the previous reports showed that nanoparticles induce stronger adjuvant activity than microparticles, 
these nanoparticles in literature were actually made of different components. Besides particle size, 
other factors such as components also determine the level of immune response induced by the 
particles.   
The optimisation of particle size of nanoparticles was performed based on previous reports in the 
literature that are deemed to induce immune response. As the reviewer suggests, the literature 
discusses nanoparticles (see list of literature below) made of different components. The important 
point is that the polymeric nanoparticles made of either natural or synthetic polymers and different 
types of polymers have all induced an immune response, however, the only difference being the level 
of immune response generated. We have safely assumed that the polymeric nanoparticles we have 
prepared using PGA-co-PDL would therefore generate an immune response if the size would be 
optimised in an appropriate range. This paper thus only discusses about the potential of using these 
PGA-co-PDL polymeric nanoparticles for vaccine delivery based on size. Now that we have shown the 
ability to maintain the structure of the model protein/antigen BSA (SDS-PAGE and CD) and 77% 
activity relative to standard, the potential of this delivery system to be evaluated for an actual antigen 
(Pneumococcal protein, as mentioned in the earlier response to the reviewer) delivery system is 
enhanced. In our future paper, we are aiming to assess the role of nanoparticles to effectively act as 
adjuvant and enhance the generated immune response compared to antigen alone and other 
polymeric NPs. 
Some examples of research papers using different polymeric NPs for vaccine delivery 
· Functionalized “Pathogen-like” Polyanhydride Nanoparticles Target C-Type Lectin 
Receptors on Dendritic Cells. Molecular Pharmaceutics (2011) 8:1877-1886 
· Targeted PLGA nano- but not microparticles specifically deliver antigen to human dendritic 
cells via DC-SIGN in vitro. Journal of Controlled Release (2010) 144:118-126 
· Delivery of antigen using a novel mannosylated dendrimer potentiates immunogenicity in 
vitro and in vivo. European Journal of Immunology (2008) 38:424-436 
· Diphtheria toxoid-containing microparticulate powder formulations for pulmonary 
vaccination: Preparation, characterization and evaluation in guinea pigs. Vaccine (2007) 
25:6818-29 
· Active targeting of dendritic cells with mannan-decorated PLGA nanoparticles. Journal of 
Drug Targeting (2011) 19:281-292 
 
Response to Reviewer Comments
2) A very small change in protein structures, for example, a change in one amino acid or tertiary 
structure, can inactivate the proteins. These small changes can not be detected by SDS-PAGE and CD. 
Additionally, the CD result showed that there was decrease in helix content and increase in β-sheet 
content of BSA released from the nanoparticles. Without doing activity assay, it is suspicious that 
these protein released were still active. 
Please provide the experimental evidence that these nanocarriers with and without protein can induce 
immune response to support the conclusion of vaccine delivery. 
The activity of BSA has been now been investigated and reported in sections 2.8.8 (methods), 3.4.5 
(results) and 4.2 (discussion). 
2.8.8 BSA Activity 
The activity of BSA was investigated using 4-Nitrophenyl acetate esterase substrate (NPA, Sigma 
Aldrich, UK) as described by Abbate et al [36]. Briefly, 1.2 ml of released BSA sample (50 µg/ml) in PBS 
was added to freshly prepared NPA solution (15 μl of a 5 mM solution in ACN) and incubated for 1 h 
using HulaMixerTM Sample Mixer. Thereafter, the solution was transferred to a plastic cuvette and 
absorbance measured at 405 nm. For positive control, standard BSA (50 µg/ml) was treated exactly the 
same as released sample whereas for negative control, PBS buffer alone was treated as sample. The 
relative residual esterolytic activity of the samples was calculated as the ratio of absorbance between 
the released BSA/standard BSA, with the esterolytic activity obtained for standard BSA considered to 
be 100%. 
3.4.5 Protein Stability (SDS-PAGE and CD) and Activity 
The residual esterolytic activity of the released BSA sample was calculated to be 77.73±3.19% relative 
to standard BSA. 
4.2 Nanocomposite Microparticles Characterization 
It is established that BSA possesses an enzyme-like activity with the ability to hydrolyse substrates 
such as p-nitophenyl esters [36,49,50]. In this study, the released BSA sample retained approximately 
77% of relative residual esterolytic activity compared to standard BSA. A reduction in BSA activity to 
60% was also observed by Abbate et al when released from biohybrid hydrogels [36]. The adsorption 
and desorption process of BSA could have influenced the structure (evident from a decreased helicity 
determined by CD) and thus the activity. However, the retention of 77% ester hydrolysis activity would 
encourage the exploration of the delivery system for further usage. 
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ABSTRACT 
Purpose: Dry powder vaccine delivery via the pulmonary route has gained significant 
attention as an alternate route to parenteral delivery. In this study, we investigated bovine 
serum albumin (BSA) adsorbed poly(glycerol adipate-co-ω-pentadecalactone), PGA-co-PDL 
polymeric nanoparticles (NPs) within L-leucine (L-leu) microcarriers for dry powder 
inhalation. 
Methods: NPs were prepared by oil-in-water single emulsion-solvent evaporation and 
particle size optimised using Taguchi’s design of experiment. BSA was adsorbed onto NPs at 
different ratios at room temperature. The NPs were spray-dried in aqueous suspension of L-
leu (1:1.5) using a Büchi-290 mini-spray dryer. The resultant nanocomposite microparticles 
(NCMPs) were characterised for toxicity (MTT assay), aerosolization (Next Generation 
Impactor), in vitro release study and BSA was characterized using SDS-PAGE and CD 
respectively. 
Results: NPs of size 128.50±6.57nm, PDI 0.07±0.03 suitable for targeting lung dendritic 
cells were produced. BSA adsorption for 1h resulted in 10.23±1.87µg of protein per mg of 
NPs. Spray-drying with L-leu resulted in NCMPs with 42.35±3.17% yield. In vitro release 
study at 37°C showed an initial burst release of 30.15±2.33% with 95.15±1.08% over 48h. 
Aerosolization studies indicated fine particle fraction (FPF%) dae<4.46μm as 76.95±5.61% 
and mass median aerodynamic diameter (MMAD) of 1.21±0.67µm. The cell viability was 
87.01±14.11% (A549 cell line) and 106.04±21.14% (16HBE14o- cell line) with L-leu based 
NCMPs at 1.25mg/ml concentration after 24h treatment. The SDS-PAGE and CD confirmed 
the primary and secondary structure of the released BSA. 
Conclusion: The results suggest that PGA-co-PDL/L-leu NCMPs may be a promising carrier 
for pulmonary vaccine delivery due to excellent BSA adsorption and aerosolization 
behaviour. 
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ABBREVIATIONS 
APCs  Antigen presenting cells 
BSA  Bovine serum albumin 
DCs  Dendritic cells 
DoE  Design of experiment 
LN  Lymph node 
NPs  Nanoparticles 
NCMPs Nanocomposite microparticles 
PGA-co-PDL poly(glycerol adipate-co-ω-pentadecalactone) 
PLA  polylactide or poly-L-lactic acid 
PLGA  poly lactic-co-glycolic-acid 
PVA  polyvinyl alcohol 
SD  Spray-drying 
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1. Introduction 
Vaccination refers to induction of an immune response using antigens coupled with adjuvants 
for generating a protective immunity against plausible future infections [1,2]. Traditional 
vaccines are often administered via the parenteral route requiring infrastructure such as cold-
chain, sterilized water for reconstitution of dry powder vaccines and trained medical 
personnel. Lack of these facilities in low and middle income countries (LMIC) is leading to 
many eligible children and adults not getting vaccinated [3]. Moreover, the majority of the 
potential vaccines in development employ purified subunits or recombinant proteins that are 
often poorly immunogenic thus needing adjuvants and effective delivery systems to generate 
an optimal immune response [1,2]. To address these issues, particulate delivery systems and 
non-invasive routes of delivery are being investigated. The pulmonary route has gained 
significant attention for delivery of vaccines as it is one of the main entry portals for 
pathogens, and can address some of the challenges such as invasiveness, cold-chain 
requirement, and stability of the antigen by delivering the antigen as a dry powder [3]. 
Biodegradable polymeric nanoparticles (NPs) have gained significant attention and are 
largely being explored as delivery vehicles for delivery of peptides, proteins, antigens, DNA 
etc. [3–5]. These polymers offer controlled or sustained drug release, biocompatibility with 
surrounding cells and tissues, degrade into low molecular weight non-toxic products and act 
as adjuvants helping in generating cellular and humoral immune responses [1,3,6]. In this 
current investigation we aim to use poly(glycerol adipate-co-ω-pentadecalactone), PGA-co-
PDL, a biodegradable polyester polymer, that has extensively been studied by our group for 
delivery of both small molecule and model drugs (dexamethasone phosphate, ibuprofen, 
sodium fluorescein), and large molecule drugs (α-chymotrypsin, DNase I) [7–10]. 
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In these biodegradable polymeric nanoparticulate formulations, the vaccine antigens (i.e. 
proteins, peptides etc.) are either adsorbed onto the surface or encapsulated within the 
particles [3]. Encapsulated antigens are protected by polymeric nanoparticles and their release 
can be modified by tailoring the properties of the polymers. Adsorbed antigen, however, 
offers enhanced stability and activity over the encapsulated antigen by avoiding contact with 
organic solvents employed during particle preparation steps [11–13]. 
Recent strategies for effective vaccine delivery have been to target the dendritic cells (DCs), 
the true professional antigen presenting cells (APCs) [14]. DCs have the exceptional ability to 
internalize, and in lymph nodes (LNs) they process and present antigens through major 
histocompatibility complex (MHC) class I and II pathways thereby activating naïve T-cells 
resulting in induction of a strong immune response [3,14,15]. A study conducted by 
Manolova et al indicates the importance of particle size in determining the uptake by DCs, 
where it was shown that upon intracutaneous injection of polystyrene beads of varying sizes, 
large particles (500–2000 nm) associated with DCs from the site of injection whereas small 
particles (20–200 nm) drained freely to the LNs and were present in LN resident DCs [15]. In 
addition, Kim et al have also shown that uptake of 200 nm sized NPs by bone marrow DCs to 
be more than that of 30 nm sized NPs [16]. Furthermore, Foged et al has shown that particle 
size of 500 nm or below were preferred and have shown fast and efficient up take by human 
DCs derived from blood [17]. The above literature suggests that smaller particles of 200 to 
500 nm could effectively be up taken by DCs and thus generates a stronger immune response 
compared to vaccine alone. However, these studies cannot be directly compared to lung DCs 
but owing to the lack of information on the effect of NP size on uptake by lung DCs the same 
can be assumed. 
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In this study, the Taguchi L18 orthogonal array design of experiment (DoE) was used to 
optimize the formulation parameters to achieve NPs (~150 nm) for targeting the lung DCs. 
The literature suggests that factors such as molecular weight (MW) of the polymer, organic 
solvent, aqueous phase, sonication time and stirrer speed have an influence on the size of the 
resultant NPs [18–20] and these were evaluated using the experimental design. 
As a dry powder, the nanosized particles cannot be directly used for inhalation as their size is 
too small and it is expected that majority of the inhaled dose will be exhaled depositing very 
minimal doses in the lung [21]. Thus, these nanoparticles are formulated into nanocomposite 
microparticles (NCMPs) using additives such as lactose [22], L-leucine [22,23], 
trehalose[24], mannitol [24] by various manufacturing techniques such as freeze drying, 
spray drying, spray-freeze drying or supercritical fluid technologies [3,25]. The NCMPs in 
the size range of 1 to 5 μm in diameter are reported to be deposited in the respirable airways 
and periphery of the lung [26]. The additives used to form NCMPs dissolve upon 
encountering the respiratory environment thereby releasing the NPs [27]. 
In this project, we aim to produce PGA-co-PDL NPs of optimum size to be effectively taken 
up by the DCs, surface adsorb a model protein, bovine serum albumin (BSA) and formulate 
into nanocomposite microparticles (NCMPs) using L-leucine as a carrier for delivery via dry 
powder inhalation. 
2. Materials and Methods 
2.1. Materials 
Dichloromethane (DCM) was purchased from BDH, laboratory supplies, UK. Novozyme 435 
(a lipase from Candida antartica immobilized on a microporous acrylic resin) was purchased 
from Biocatalytics, USA. Acetonitrile (HPLC grade), albumin tagged with fluorescein 
isothiocyanate (FITC-BSA), bovine serum albumin (BSA, MW 67 KDa), phosphate buffered 
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saline (PBS, pH 7.4) tablets, poly(vinyl alcohol) (PVA, MW 9–10 KDa, 80%), trifluoroacetic 
acid (TFA, HPLC grade), RPMI-1640 medium with L-glutamine and NaHCO3, thiazoly blue 
tetrazolium bromide (MTT), tween 80
®
 and ω-pentadecalactone were obtained from Sigma-
Aldrich, UK. L-leucine (L-leu) was purchased from BioUltra, Sigma, UK. 75 cm
2
/tissue 
culture flasks with vented cap, 96-well flat bottom plates, acetone, antibiotic/ antimycotic 
solution (100X), dimethyl sulfoxide (DMSO) were purchased from Fisher Scientific, UK. 
Divinyladipate was obtained from Fluorochem, UK. Fetal calf serum (FCS) heat inactivated 
was purchased from Biosera UK. poly(glycerol adipate-co-ω-pentadecalactone) (PGA-co-
PDL, MW of 14.7, 24.0 KDa was synthesized in our laboratory at LJMU and micro BCA™ 
protein assay kit was purchased from Thermo Scientific, UK. A549 cell line was purchased 
from ATCC. 16HBE14o- cells were obtained from Dr Dieter Gruenert from the California 
Pacific Medical Center, University of California San Francisco, USA. 
2.2. Polymer Synthesis 
The PGA-co-PDL polymer of MW of 14.7, 24.0 KDa was synthesized in our laboratory via 
enzyme catalyzed co-polymerization of three monomers as described by Thompson et al. 
[28]. The synthesized linear polyester was characterized by gel permeation chromatography, 
GPC (Viscotek TDA Model 300 using OmniSEC3 operating software), pre-calibrated with 
polystyrene standards (polystyrene standards kit, Supelco, USA), and 
1
H-NMR spectroscopy 
(Bruker AVANCE 300  MHz, Inverse probe with B-ACS 60, Auto sampler with gradient 
chemming) as described by Thompson et al. [28]. 
2.3. Preparation of Nanoparticles 
The PGA-co-PDL NPs were fabricated using a modified oil-in-water (o/w) single emulsion 
solvent evaporation method [29]. Briefly, 200 mg PGA-co-PDL polymer (MW 14.7 KDa) 
(and Nile Red, NR 0.5 mg for characterization of protein adsorption onto the surface of PGA-
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co-PDL via confocal microscopy) was dissolved in 2 ml DCM and probe sonicated (20 
microns amplitude) upon addition to 5 ml of 10% w/v poly(vinyl alcohol) (PVA) (1
st
 aqueous 
solution) for 2 min to obtain an emulsion. This whole process was performed using ice. This 
was immediately added drop wise to 20 ml of 2
nd
 aqueous solution (0.75% w/v PVA) under 
magnetic stirring at a speed of 500 RPM. The whole mixture was left stirring at room 
temperature for 3 h to facilitate the evaporation of DCM. The particle size, PDI and zeta-
potential were then characterised as mentioned in section 2.6. The NP suspensions were 
collected by centrifugation (78,000g, 40 min, 4°C) and surface adsorbed with protein as 
indicated in section 2.5. 
2.4. Taguchi Design of Experiment (DoE) 
In order to evaluate the influence of formulation parameters and minimize the number of 
experiments, Taguchi DoE being appropriate to study large number of factors, was employed 
through Minitab
®
 16 Statistical Software. Seven factors, namely, polymer MW, organic 
solvent, internal aqueous phase concentration and volume, sonication time, stirrer speed and 
external aqueous phase concentration were evaluated by constructing and using L18 
orthogonal array design with 1 factor, MW, at 2 levels and remaining 6 factors at 3 levels 
(Table I). 
The design was applied to identify the significant factors that would affect the size of PGA-
co-PDL NPs. Optimum conditions were indicated by high signal-to-noise (S/N) ratios, where 
signal factor (S) is the outcome, the particle size, and noise factors (N) are parameters such as 
humidity, temperature, experience of the experimenter etc. A greater S/N ratio corresponds to 
minimum variance of the outcome, the particle size i.e. a better performance. In other words, 
the experimental parameter having the least variability is the optimum condition [30]. The 
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optimization of size was carried out using the Taguchi’s ‘smaller-is-better’ criterion i.e. to get 
the outcome, the particle size, to an ideal target of zero or as small as possible. 
2.5. Protein Adsorption 
NP suspension (equivalent to 10 mg i.e. 1.25 ml of suspension) was centrifuged (78,000g, 40 
min, 4°C) and the resultant pellet was resuspended in vials containing 4 ml of BSA (or FITC-
BSA for characterization of protein adsorption onto the surface of PGA-co-PDL via confocal 
microscopy), for 1 h, at different ratios of 100: 4, 100: 10 and 100: 20 (NPs: BSA) 
corresponding to 100, 250 and 500 µg/ml BSA concentrations, respectively. The resulting 
suspension (for 100: 20) was left rotating for 30 min, 1, 2 and 24 h at 20 RPM on a 
HulaMixer
TM
 Sample Mixer (Life Technologies, Invitrogen, UK). After respective time 
points, the protein adsorbed NP suspensions were centrifuged and the supernatant analysed 
for protein content using micro BCA protein assay kit. The amount of BSA adsorbed per 
milligram of NPs (n=3) was calculated using eq. 1: 
A  or  io        r m  o          i i    ro  i  co c-    r        ro  i  co c 
Amo    o     
 (1) 
The particle size and PDI were then characterised as mentioned in section 2.6. 
2.6. Nanoparticle Characterization 
Particle size, poly dispersity index (PDI, a number between 0 and 1 describing the 
homogeneity of the sample) and zeta-potential were measured by laser diffraction using a 
laser particle size analyser (Zetasizer Nano ZS, Malvern Instruments Ltd, UK). For NPs 
suspension, an aliquot of 100 µl was diluted with 5 ml of deionized water and for NP 
suspensions with and without BSA adsorption, 2 mg of NPs were resuspended in 5 mL of 
deionized water, loaded into a cuvette and the measurements were recorded at 25°C (n=3). 
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2.7. Nanocomposite Microparticles 
Spray-drying was employed to incorporate the NPs into nanocomposite microparticles 
(NCMPs) using L-leucine as a carrier, and at nanoparticles-to-carrier ratio of 1:1.5 w/w. 
Blank NPs, BSA-loaded NPs or FITC-BSA-loaded NR NPs were dispersed in 20 ml water 
with L-leucine dissolved and spray-dried using a Büchi B-290 mini spray-dryer (Büchi 
Labortechnik, Flawil, Switzerland) with a nozzle atomizer, and nozzle orifice diameter of 0.7 
mm. The spray-drying was performed at a feed rate 10%, an atomizing air flow of 400 L/h, 
aspirator capacity of 100% and an inlet temperature of 100°C (outlet temperature 
approximately 45 - 47°C). The dry particles (PGA-co-PDL/L-leu NCMPs) were separated 
from the air stream using a high-performance cyclone (Büchi Labortechnik), and the dry 
particles were collected and stored in desiccator until further use. 
2.8. Nanocomposite microparticles Characterization 
2.8.1. Yield 
The dry powder yield was determined as the difference in the weight of the sample vial 
before and after product collection. The weight difference was compared to the initial total 
dry mass and the yield in % (w/w) was calculated (n=3). 
2.8.2. Particle Size and Morphology 
To confirm the recovery of NPs from NCMPs with an appropriate size range for cellular 
uptake, particle size and PDI of NPs following re-dispersion of blank and loaded NCMPs in 
water were measured. The measurements were recorded as mentioned in section 2.6, where 5 
mg of NCMPs were dispersed in 2 ml of deionized water then loaded into a cuvette and the 
measurements were recorded at 25°C (n=3). 
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Spray dried PGA-co-PDL/L-Leu NCMPs samples were mounted on aluminium stubs (pin 
stubs, 13 mm) layered with a sticky conductive carbon tab and coated with palladium (10-15 
nm) using a sputter coater (EmiTech K 550X Gold Sputter Coater, 25 mA for 3 min). The 
particles were then visualized using scanning electron microscopy (FEI Quanta™ 200 ESEM, 
Holland). 
2.8.3. Confocal Laser Scanning Microscopy 
FITC-BSA-loaded NR NPs spray-dried into NCMPs were observed under confocal 
microscope to visualise the adsorption of BSA onto the NPs. Briefly, a Zeiss 510 Meta laser 
scanning microscope mounted on a Axiovert 200 M BP computer-controlled inverted 
microscope was used to obtain the confocal images. A few milligrams of spray-dried NCMPs 
were placed in a single well of 8-well chambered (Fisher Scientific, UK) and imaged by 
excitation at a wavelength of 488 nm (green channel for FITC-BSA), 543 nm (red channel for 
Nile Red NPs) and a Plan Neofluar 63×/0.30 numerical aperture (NA) objective lens. Image 
analysis was carried out using the Zeiss LSM software. 
2.8.4. Protein Quantification by HPLC 
An HPLC method was developed to quantify the amount of BSA present in NCMPs. The 
chromatographic conditions were as follows: HPLC system Agilent 1100 series (Santa Clara, 
CA, USA) equipped with a column (Aeris 3.6 μm C4 200A Wide Pore 4.6mm i.d. x 150 mm 
length), security cartridge of the same material (Phenomenex, UK) and software for data 
processing; mobile phase was composed of (A) 0.1% TFA in water and (B) 0.1% TFA in 
acetonitrile with a gradient flow of A/B from 80:20 to 35:65 in 25 min, post-time 6 min; flow 
rate of 0.8 ml/min; injection volume of 100 μl; run temperature 40°C; UV detection at 214 
nm and BSA retention time of 14.4 min. BSA calibration curve was prepared by accurate 
dilution of a previously prepared stock solution (1 mg/ml) in HPLC water and PBS (pH 7.4) 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
to obtain the following concentrations: 0.5, 1, 2.5, 5, 10, 25, 50, 100 and 200 μg/ml of BSA 
(n = 9, R
2
 = 0.999). All solutions used in the process were filtered using 0.45 μm filters prior 
to use. Limit of Detection (LOD) in water – 1.98 μg/ml, PBS – 1.48 μg/ml and Limit of 
Quantification (LOQ) in water – 3.24 μg/ml, PBS – 3.20 μg/ml. 
2.8.5. In vitro Release Studies 
BSA adsorbed PGA-co-PDL/L-leu NCMPs (20 mg) were transferred into eppendorfs and 
dispersed in 2 ml of PBS, pH 7.4. The samples were incubated at 37C and left rotating for 
48 h at 20 RPM on a HulaMixer
TM
 Sample Mixer (Life Technologies, Invitrogen, UK). At 
pre-determined time intervals up to 48 h, the samples were centrifuged (accuSpin Micro 17, 
Fisher Scientific, UK) at 17,000g for 30 min and 1 ml of the supernatant removed and 
replaced with fresh medium. The supernatant was analysed using the HPLC method as 
mentioned above. Each experiment was repeated in triplicate and the result was the mean 
value of three different samples (n=3). The percentage cumulative BSA released was 
calculated using eq. 2: 
  C m    i   B A r          C m    i   B A r       
B A  o    
         (2) 
2.8.6. Sodium Dodecyl Sulfate-Polyacrylamide Gel Electrophoresis (SDS-
PAGE) 
The primary structure of BSA released from the NCMPs after spray-drying was determined 
by SDS-PAGE. SDS-PAGE was performed on CVS10D omniPAGE vertical gel 
electrophoresis system (Geneflow Limited, UK) with 9% stacking gel prepared using 
ProtoGel stacking buffer (Geneflow Limited, UK) containing 0.4% of SDS. Protein 
molecular weight markers in the range 10–220 KDa (Geneflow Limited, UK) and BSA were 
used as control. The protein loading buffer blue (2X) (0.5M Tris-HCl (pH 6.8), 4.4% (w/v) 
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SDS, 20% (v/v) Glycerol, 2% (v/v) 2- mercaptoethanol and bromphenol blue in 
distilled/deionised water) was added to the samples in 1:1 (v/v) buffer-to-sample ratio. After 
loading the samples (25 μl sample per well), the gel was run for approximately 2.5 h at a 
voltage of 100 V with Tris-Glycine-SDS PAGE buffer (10X) (Geneflow Limited, UK) 
containing 0.25M Tris base, 1.92M glycine and 1% (w/v) SDS. The gel was stained with 
colloidal coomassie blue and then destained in distilled water overnight. An image of the gel 
was scanned on a gel scanner (GS-700 Imaging Densitometer, Bio-Rad) equipped with 
Quantity One software. 
2.8.7. Circular Dichroism (CD) 
The secondary structure of standard BSA (control), BSA supernatant (after 1 h adsorption 
followed by centrifugation) and BSA released from NPs after 48 h was determined by 
measuring circular dichroism spectra. All CD experiments were performed using a J-815 
spectropolarimeter (Jasco, UK) at 20 °C as previously described [31]. Five scans per sample 
using a 10 mm path-length cell were performed over a wavelength range 260 to 180 nm at a 
data pitch of 0.5 nm, band width of 1 nm and a scan speed 50 nm min
-1
. Far-UV CD spectra 
were collated for standard BSA, supernatant BSA in HPLC grade water, BSA released in 
PBS for 48 h. For all spectra, the baseline acquired in the absence of sample was subtracted 
[32]. The secondary structure of the samples was estimated using using the CDSSTR method 
[33] from the DichroWeb server [33–35]. 
2.8.8. BSA Activity 
The activity of BSA was investigated using 4-Nitrophenyl acetate esterase substrate (NPA, 
Sigma Aldrich, UK) as described by Abbate et al [36]. Briefly, 1.2 ml of released BSA 
sample (50 µg/ml) in PBS was added to freshly prepared NPA solution ( 5 μl of a 5 mM 
solution in ACN) and incubated for 1 h using HulaMixer
TM
 Sample Mixer. Thereafter, the 
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solution was transferred to a plastic cuvette and absorbance measured at 405 nm. For positive 
control, standard BSA (50 µg/ml) was treated exactly the same as released sample whereas 
for negative control, PBS buffer alone was treated as sample. The relative residual esterolytic 
activity of the samples was calculated as the ratio of absorbance between the released 
BSA/standard BSA, with the esterolytic activity obtained for standard BSA considered to be 
100%. 
2.8.9. In vitro Aerosolization Studies 
The Next Generation Impactor (NGI) was employed to assess the aerosol performance of 
spray-dried NCMPs. The BSA adsorbed NCMPs were weighed (4 capsules each 
corresponding to 12.5 mg Spray-dried, SD, powder equivalent to 5 mg of NPs) and manually 
loaded into the hydroxypropyl methylcellulose, HPMC, capsule (size 3), and placed in a 
Cyclohaler® (Teva pharma). The samples were drawn through the induction port into the 
NGI using a pump (Copley Scientific, Nottingham, UK) operated at a flow rate of 60 L/min 
for 4 s. The plates were coated with 1% tween 80: acetone solution and samples collected 
using a known volume of distilled water, and left on a roller-shaker for 48 h for the BSA to 
be released from NCMPs. The samples were centrifuged using an ultracentrifuge (as 
mentioned in section 2.3) and the supernatants analysed using HPLC method as mentioned 
above to determine the amount of BSA deposited. The Fine Particle Fraction (FPF, %) was 
determined as the fraction of emitted dose deposited in the NGI with dae< 4.46 μm, the mass 
median aerodynamic diameter (MMAD) was calculated from log-probability analysis, and 
the fine particle dose (FPD) was expressed as the mass of drug deposited in the NGI 
dae < 4.46 μm (n=3). 
2.8.10. Cell Viability Study 
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The in vitro cytotoxicity of the empty PGA-co-PDL/L-leu NCMPs was evaluated using the 
MTT assay. The adenocarcinomic human alveolar basal epithelial cell line, A549 (passage 
no. 32) or 16HBE14o- cells (passage no. 32) were seeded in 100 μl (2.5 × 105 cells/ml) of 
RPMI-1640 medium supplemented with 10% fetal calf serum/1% Antibiotic/Antimycotic 
solution (complete medium) in 96-well plates and placed in an incubator at 37°C for 24 h 
supplemented with 5% CO2. Then, 100 μl of freshly prepared NCMP dispersions in complete 
medium were added to the wells to an appropriate concentration (0 - 2.5 mg/ml) (n = 3), and 
10% dimethyl sulfoxide (DMSO) as a positive control. The formulations were assayed for 
toxicity over 24 h of incubation, followed by the addition of 40 μl of a 5 mg/ml MTT solution 
in PBS to each well. After 2 h of incubation at 37°C, the culture medium was gently removed 
and replaced by 100 μl of dimethyl sulfoxide in order to dissolve the formazan crystals. The 
absorbance of the solubilised dye, which correlates with the number of living cells, was 
measured at 570 nm using a plate reader (Molecular Devices, SpectraMAX 190). The 
percentage of viable cells in each well was calculated as the absorbance ratio between 
nanoparticle-treated and untreated control cells. 
2.9. Statistical Analysis 
All statistical analysis was performed using Minitab
®
 16 Statistical Software. One-way 
analysis of variance (ANOVA) using Minitab
®
 16 Statistical Software with the Tukey’s 
comparison was employed for comparing the formulations with each other. Statistically 
significant differences were assumed when p < 0.05. All values are expressed as their mean ± 
standard deviation. 
3. Results 
3.1. Polymer Synthesis 
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The synthesized PGA-co-PDL co-polymer (monomer ratio, 1:1:1) was a white powder with a 
molecular weight of 14.7, 24.0 KDa for 6 h, 24 h as determined by the GPC. The integration 
pattern of the co-polymer was confirmed by 
1
H-NMR spectra, (δH CDCl3, 300 MHz): 1.34 
(s, 22 H, H-g), 1.65 (m, 8 H, H-e, e′, h), 2.32 (m, 6 H, H-d, d′, i), 4.05 (q)-4.18 (m) (6 H, H-a, 
b, c, f), 5.2 (s, H, H-j). 
3.2. Taguchi Design of Experiment (DoE) 
The Taguchi design was applied in this study to identify the significant factors that would 
influence the size of PGA-co-PDL NPs. Considering seven factors (1 factor at 2 levels and 6 
factors at 3 levels) to be investigated, non-usage of an experimental design would have 
resulted in 2*3
6
 = 1458 individual experiments which would be an arduous task and 
inefficient. The Taguchi L18 orthogonal array design resulted in 18 runs to be performed to 
yield the optimum conditions for each factor in achieving the smallest PGA-co-PDL NP size. 
Table II illustrates the structure of the L18 orthogonal array, the corresponding results and S/N 
ratios. 
The results obtained from 18 runs indicated particle sizes ranging from 138.7±6.4 (run 3) to 
459.4±69.5 (run 11). Figure 1 shows the mean S/N graph of the particle size for each 
parameter level. The parameter with the largest range and corresponding rank (indicates the 
relative importance compared to other parameters) was considered as the critical factor 
affecting that particle size. 
Analysis of the particle sizes of 18 runs using the Taguchi’s ‘smaller-is-better’ criterion in 
Minitab
®
 16 Statistical Software, the optimum conditions inferred from the range, rank and 
the S/N response graph were A1B3C3D3E2F2G2. The optimum formulation made using 
these conditions yielded NPs with a size of 128.50±6.57 nm lower than the minimum size of 
138.7±6.4 nm obtained using run 3, PDI of 0.07±0.03 and zeta-potential of -10.2±3.75 mV. 
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3.3. Protein Adsorption 
Figure 2a shows the amount of BSA adsorbed per mg of NPs for different concentrations of 
BSA loaded. The average adsorption of BSA, μg per mg of NPs, increased significantly from 
100: 4 (NP: BSA) loading concentration (4.75±0.39), 100: 10 (6.59±1.28) to 100: 20 
(10.23±1.87) (p < 0.05, ANOVA/Tukey’s comparison). 
Figure 2b shows the amount of BSA adsorbed in μg per mg of NPs at different time points 
for 100: 20 (NP: BSA) loading concentration. The average adsorption increased significantly 
from 30 min (1.84±0.82) to 1 h (10.23±1.87) (p < 0.05, ANOVA/Tukey’s comparison) with 
no significant difference beyond 1 h compared to that of 2 h (8.76±0.34) and 24 h 
(8.95±0.39) (p > 0.05, ANOVA/Tukey’s comparison) indicating maximum adsorption at 1 h. 
Table III lists the particle size and PDI of PGA-co-PDL NPs with and without BSA 
adsorption. As seen, there is a significant increase    <  . 5, A OVA/T k y’  com  ri o   
in size which is attributed to the adsorption of BSA onto NPs as confirmed using confocal 
microscopy (section 3.4.3). 
3.4. Nanocomposite Microparticles Characterization 
3.4.1. Yield 
A reasonable yield of spray drying, 40.36±1.80 % for the empty PGA-co-PDL NCMPs and 
42.35±3.17 % for the BSA adsorbed PGA-co-PDL/L-leu NCMPs was obtained. 
3.4.2. Particle Size and Morphology 
The size of NPs after recovery from spray-dried blank NCMPs in water was 210.03 ± 15.57 
nm and PDI 0.355 ± 0.067 and for that of BSA loaded NCMPs was 282.46 ± 2.17 nm and 
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PDI 0.36 ± 0.008, which is in the range of 200 to 500 nm for uptake by dendritic cells (DCs) 
[16-18]. 
The shape and surface texture of NCMPs were investigated using scanning electron 
microscopy (Fig. 3). Photomicrographs of NCMPs showed irregular and corrugated 
microparticles. 
3.4.3. Confocal Laser Scanning Microscopy 
CLSM was used to observe the interaction of BSA with NPs. The microscopic images in Fig. 
4a (split view) and 4b (orthogonal view) shows the spray-dried NCMPs containing the 
fluorescent nanoparticles (red, labelled using NR dye) adsorbed with FITC-BSA (green). The 
image shows that FITC-BSA was evidently only present where the NPs were present, 
indicating their association. Moreover, the increase in size observed after adsorption also 
confirms the adsorption of BSA onto PGA-co-PDL NPs (Table III). 
3.4.4. In vitro Release Studies 
In vitro release studies were performed on NCMPs and reported as cumulative percentage 
BSA released over time (Fig. 5). An initial burst release of 30.15±2.33 % (BSA) was 
observed followed by continuous release up to 5 h, with BSA release of 86.07±0.95 %. After 
this time period, a slow continuous release of BSA was observed with release of 95.15±1.08 
% over 48 h, indicating an excellent release profile for the PGA-co-PDL/L-leu NCMPs. 
3.4.5. Protein Stability (SDS-PAGE and CD) and Activity 
The primary structure of BSA released from the NCMPs was investigated using SDS-PAGE 
analysis. Figure 6 reveals identical bands for the standard BSA and desorbed BSA from 
NCMPs without any newly noticeable bands of high and low molecular BSA. 
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The secondary structure analysis was performed using CD spectral data. Figure 7a and 7b 
shows the structure of standard BSA, BSA supernatant and BSA released. In Fig 7a, the CD 
spectra show minima at 221 - 222 and 209 – 210 nm and maximum at about 195 nm for both 
samples, which is characteristic of α-helical structure. Further structural analysis showed that 
the predominant structure of the peptide was helical displaying 51 and 62.5% helicity 
respectively (Table IV). Moreover, the experimental data obtained for the standard BSA are 
in good agreement with previous reports [37]. Figure 7b shows that BSA released displayed 
double minima at 208 and 222 nm and further spectra analysis indicated this sample adopted 
a reduced level helical conformation (circa 36% helical) (Table IV). Comparing the CD 
results of BSA released with that of standard BSA, the content of α-helix decreases by 15%, 
the β-sheet content increases by 8.9%, the turns content increases by 1%, and the random 
coils’ content increases by 3%, respectively. 
The residual esterolytic activity of the released BSA sample was calculated to be 
77.73±3.19% relative to standard BSA. 
3.4.6. In vitro Aerosolization Studies 
The deposition data obtained from spray-dried formulations displayed a FPD of 
112.87±33.64 µg, FPF of 76.95±5.61 % and MMAD of 1.21±0.67 μm. This suggest that the 
BSA adsorbed PGA-co-PDL/L-leu NCMPs were capable of delivering efficient BSA to the 
lungs, and are expected to deposit the majority of the emitted dose to the bronchial-alveolar 
region of the lungs [3]. 
3.4.7. Cell Viability Study 
The non-adsorbed PGA-co-PDL NCMPs appear to be well tolerated by both the cell lines, 
with a cell viability of 87.01±14.11 % (A549 cell line) and 106.04±21.14 % (16HBE14o- cell 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
line) (Fig. 8) at 1.25 mg/ml concentration after 24 h exposure indicating a good toxicity 
profile without any significant difference in cell viability between particle loadings. This 
provides an indication about the feasibility of using PGA-co-PDL polymers as safe carriers 
for pulmonary drug delivery. 
4. Discussion 
4.1. Nanoparticle Preparation and Characterization 
The PGA-co-PDL NPs were prepared using a modified oil-in-water (o/w) single emulsion 
solvent evaporation method [29]. The results of 18 runs, suggested by Taguchi’s L18 
orthogonal array, resulted in NPs of size < 150 nm. However, this increases to about 200 - 
300 nm after centrifugation and BSA adsorption. This according to the literature suggests  an 
effective uptake by DCs [15–17]. The effects of each factor are discussed in detail below: 
Factor D, PVA concentration (range = 3.17, rank = 1), is the most important factor affecting 
the particle size. The S/N ratios at three levels indicated that particle size almost linearly 
decreased with increase in surfactant concentration from 2.5 to 10% w/v (S/N ratio, r
2
 = 
0.997). The particle size decreases because at lower concentrations there is inadequate 
amount of surfactant to cover all the surfaces of PGA-co-PDL NPs [38]. The uncovered NPs 
then tend to aggregate until a point where there is adequate amount of surfactant to cover the 
total surface area of the aggregated NPs, and form a stable system leading to larger particles. 
However, with an increase in surfactant concentration it was possible to efficiently cover all 
the surfaces of NPs thereby stabilizing the system avoiding aggregation and resulting in 
smaller PGA-co-PDL NPs [38]. This effect of decrease in particle size with an increase in 
surfactant concentration, PVA, was also observed by Mitra and Lin [39]. 
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The S/N ratios of factor A, molecular weight of the polymer (range = 2.19, rank = 3), at two 
levels, suggested a directly proportional relationship with MW of polymer, i.e. the particle 
size decreases with a decrease in the MW of the polymer. This can also be evident from the 
lower particle size measurements observed using 14.7 KDa MW polymer (runs 1-9) relative 
to 24 KDa MW polymer (runs 10-18). As the MW of polymer increases, the viscosity of the 
polymeric solution also increases, thereby imposing difficulty in breaking them into smaller 
emulsion droplets when compared to lower MW polymer requiring lower efficiency to 
breakdown under similar conditions. This increase in size of the particles has also been 
observed by others and is reported to be associated with high MW polymers [5,40,41] 
The S/N ratios of factor B, volume of organic solvent (DCM, range = 2.32, rank = 2), at three 
levels indicated that particle size almost linearly decreased with increase in volume from 1 to 
2 ml (S/N ratio, r
2
 = 0.999). This decrease in particle size is attributed to the decrease in 
viscosities of the polymer solution (keeping the amount and MW of polymer constant). This 
makes it easier to break into smaller emulsion droplets resulting in a decreased particle size 
as explained above. This effect could also be observed with factor C, volume of 1
st
 aqueous 
phase (range = 1.23, rank = 5), where a decrease in volume increased the viscosity thereby 
resulting in an increase in particle size. 
The S/N ratios for factor E, sonication time (range = 2.09, rank = 4), did not follow any 
particular trend; however, the 2
nd
 level was found to be the optimum for achieving smaller 
particle size. The S/N ratios for parameters F, stirrer speed (the speed at which the magnetic 
bar was rotating for evaporation of DCM in the external phase) and G, 2
nd
 PVA concentration 
have a low range of 0.34 and 0.18 respectively indicating that they have a minimal influence 
over the size of nanoparticles produced. Therefore, the optimum conditions inferred result in 
NPs of size suitable for cellular uptake into DC as established in the literature [15–17,42,43]. 
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The adsorption of BSA onto NPs is expected to be mainly driven by hydrophobic, 
electrostatic (ionic) interactions and hydrogen bonding [44]. However, in this study as the 
NPs, evident from zeta-potential values, are negatively charged and BSA in water is also 
highly negatively charged [45] suggesting that the electrostatic interactions are minimal and 
that the adsorption process is dominated by the hydrophobic interactions and hydrogen 
bonding. The BSA adsorption onto NPs increased with an increase in NP: BSA ratio from 
100: 4 to 100: 20, which was expected as the amount of BSA available for adsorption 
increased. Figure 2 (b) suggests that the surface of NPs was saturated with BSA after 1 h 
suggesting maximum adsorption with 100: 20 (NP: BSA) BSA loading concentration. 
4.2. Nanocomposite Microparticles Characterization 
NCMPs were produced by spray-drying using L-leucine as a carrier and a dispersibility 
enhancer. The SEM pictures (Fig. 3) show irregular or wrinkled surface which is due to an 
excessive build-up of vapour pressure during water evaporation in the spray drying process 
and occurs with hydrophobic amino acids, such as L-Leucine [8,46,47]. 
The release profile shows more than 90% of the BSA released within 48 h this is because of 
weaker hydrophobic interactions between BSA and NPs compared to the strong ionic 
interactions. Moreover, the identical bands observed for BSA standard and desorbed BSA 
from NCMPs suggests that protein has maintained its primary structure and was neither 
degraded nor affected by the adsorption and spray drying procedure. 
The secondary structure of BSA in the formulation was analysed using CD spectroscopy, a 
valuable technique in analysing the protein structure [31]. The BSA released samples 
confirms the presence of α-helix and β-sheets though decreased compared to standard BSA. 
However, in protein secondary structure, it is believed that the β-sheet structure is sometimes 
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observed as a special α-helix only with two amino acid residues through stretching resulting 
from the breakage of hydrogen bond [37,48]. 
It is established that BSA possesses an enzyme-like activity with the ability to hydrolyse 
substrates such as p-nitophenyl esters [36,49,50]. In this study, the released BSA sample 
retained approximately 77% of relative residual esterolytic activity compared to standard 
BSA. A reduction in BSA activity to 60% was also observed by Abbate et al when released 
from biohybrid hydrogels [36]. The adsorption and desorption process of BSA could have 
influenced the structure (evident from a decreased helicity determined by CD) and thus the 
activity. However, the retention of 77% ester hydrolysis activity would encourage the 
exploration of the delivery system for further usage. 
The FPF value suggests an excellent aerosolization performance and deep lung deposition 
profile. The surface activity of the relatively strong hydrophobic alkyl side chain of L-leucine 
accumulating at the particle surface during spray drying reduces the surface free energy of the 
dry powder and cohesive inter-particulate interactions and this might be a plausible 
explanation for the enhanced dispersibility [8,23]. In addition, the dispersibility enhancing 
property of L-leucine resulting from its corrugated surface that reduces the contact points 
between particles leads to an improved aerosolization characteristic of powders [22,47,51]. 
Similar reports have also demonstrated the enhanced aerosol performance with L-leucine 
containing formulations [22,47,51,52]. Moreover, the MMAD values show an efficient 
delivery of NCMPs containing BSA to the deep lungs mainly to the bronchial-alveolar region 
[3]. A study by Todoroff et al have shown that more intense specific immune responses could 
be achieved by targeting the antigen to the deep lungs than to the upper airways [53]. Also, 
Menzel et al have shown that upon inhalation of Pneumovax
®
, a pneumococcal 
polysaccharide vaccine, by healthy volunteers the vaccine deposited in the alveolar region 
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displayed increased serum antibody levels compared to that deposited in the larger airways 
[54]. Thus, this deposition to the deep lungs may generate stronger immune responses. 
The NGI data suggests a deposition mainly in the bronchial-alveolar region of the lungs[3], 
thus the cell viability studies were performed on A549 cell line (adenocarcinomic human 
alveolar basal epithelial cells) and 16HBE14o- cell line (human bronchial epithelial cells). 
The results show that both the cell lines were tolerant to the NCMPs up to 1.25 mg/ml 
concentration encouraging further investigation in animals. 
5. Conclusions 
PGA-co-PDL nanoparticles of appropriate size to target DCs were successfully produced 
using Taguchi L18 orthogonal array DoE. BSA adsorption onto NPs in the ratio of 100: 20 
(NPs: BSA) for 1 h at room temperature produced the maximum adsorption of BSA 
(10.23±1.87 µg of protein per mg of NPs). The BSA adsorbed NPs were successfully spray-
dried using L-leucine into NCMPs producing a yield of 42.35±3.17% and the NCMPs had 
irregular and corrugated morphology. The BSA released from the NCMPs was shown to be 
maintaining its structure under SDS-PAGE and CD analysis with 77% of relative residual 
esterolytic activity. Moreover, FPF of 76.49±6.26 % and MMAD of 1.21±0.67 μm values 
indicate deep lung deposition with NCMPs showing a low toxicity profile. This study 
suggests that PGA-co-PDL NCMPs could be used as a novel carrier for pulmonary vaccine 
delivery. 
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Table I Taguchi's Experimental Design L18 for producing PGA-co-PDL nanoparticles 
Levels Units 1 2 3 
A - MW of Polymer KDa 14.7 24.0 - 
B - Org Sol (DCM) ml 1 1.5 2 
C - Aq. Vol (PVA) ml 3 4 5 
D - 1
st
 Aq. Conc (PVA) % w/v 2.5 5 10 
E - Sonication Time min 1 2 5 
F - Stirrer Speed RPM 400 500 600 
G - 2
nd
Aq. Conc (PVA) % w/v 0.5 0.75 1 
 
Table I with caption
Click here to download Table: Table I with caption.docx 
Table II Structure of Taguchi’s L18 orthogonal array, corresponding particle size and S/N 
ratios (Mean±SD, n=6) 
Runs 
Parameters 
Particle 
Size (nm) 
PDI 
S/N 
Ratio 
(dB) A B C D E F G 
Run 1 1 1 1 1 1 1 1 315.5±6.90 0.151±0.05 -49.979 
Run 2 1 1 2 2 2 2 2 186.5±4.30 0.097±0.03 -45.412 
Run 3 1 1 3 3 3 3 3 138.7±6.40 0.093±0.01 -42.843 
Run 4 1 2 1 1 2 2 3 210.1±18.7 0.116±0.04 -46.449 
Run 5 1 2 2 2 3 3 1 208.7±49.9 0.123±0.06 -46.389 
Run 6 1 2 3 3 1 1 2 182.0± 3.20 0.075±0.04 -45.199 
Run 7 1 3 1 2 1 3 2 192.9±9.30 0.077±0.04 -45.705 
Run 8 1 3 2 3 2 1 3 149.3±2.50 0.075±0.01 -43.481 
Run 9 1 3 3 1 3 2 1 192.9±23.0 0.050±0.03 -45.704 
Run 10 2 1 1 3 3 2 2 269.1±68.9 0.205±0.04 -48.598 
Run 11 2 1 2 1 1 3 3 459.4±69.5 0.233±0.02 -53.243 
Run 12 2 1 3 2 2 1 1 242.5±19.1 0.188±0.06 -47.694 
Run 13 2 2 1 2 3 1 3 253.2±47.3 0.155±0.10 -48.069 
Run 14 2 2 2 3 1 2 1 217.3±18.9 0.116±0.01 -46.742 
Run 15 2 2 3 1 2 3 2 240.5±35.1 0.133±0.05 -47.622 
Run 16 2 3 1 3 2 3 1 169.3±7.60 0.144±0.04 -44.573 
Run 17 2 3 2 1 3 1 2 235.9±29.6 0.119±0.08 -47.453 
Run 18 2 3 3 2 1 2 3 221.7±11.0 0.150±0.04 -46.915 
A - MW of Polymer, B - Org Sol (DCM), C - Aq. Vol (PVA), D - 1st Aq. conc (PVA), E - Sonication time, F - Stirrer Speed and G - 2nd 
Aq. conc (PVA) 
Table II with caption
Click here to download Table: Table II with caption.docx 
Table III Particle size and PDI of PGA-co-PDL nanoparticles without and with BSA 
adsorption 
 
NP suspension Without BSA adsorption With  BSA adsorption 
Particle Size (nm) 128.50 ± 6.57
a
 203.9 ± 2.55
b*
 299.03 ± 32.02
c*
 
PDI 0.070 ± 0.030 0.205 ± 0.007 0.322 ± 0.060 
a 
NPs characterised immediately after preparation without centrifugation, 
b 
NPs characterised after centrifugation 
but without adsorption of BSA, 
c 
NPs characterised after centrifugation and BSA adsorption, 
*
 p < 0.05, 
ANOVA/Tukey’s comparison 
Table III with caption
Click here to download Table: Table III with caption.docx 
Table IV The percentages of the secondary structures of standard, supernatant and released 
BSA samples 
Sample Helix Strand Turns Unordered 
     
Standard BSA 51 ± 0.007 21.1 ± 0.07 6.0 ± 0.01 18 ± 0.007 
     
Supernatant BSA 62.5 ± 0.035 22.0 ± 0.021 5.5 ± 0.05 9.5 ± 0.06 
     
Released BSA 36.0 ± 0 30.0  ± 0 7.0  ± 0 21  ± 0.007 
The content and level of secondary structure elements in the peptide was calculated from spectral data using the DichroWeb server software 
as described in Methods 
Table IV with caption
Click here to download Table: Table IV with caption.docx 
Legends to Figures 
Fig. 1 Mean S/N graph for particle size response. Letters (A–E) denote the experimental 
parameters and numeric values denote the parameter levels (  indicates maximum S/N 
value) (Mean±SD, n=6); Note: A - MW of Polymer, B - Org Sol (DCM), C - Aq. Vol (PVA), D - 1st Aq. conc 
(PVA), E - Sonication time, F - Stirrer Speed and G - 2nd Aq. conc (PVA) 
Fig. 2 Amount of BSA adsorbed per mg of NPs at different (a) BSA loading concentrations 
(NP: BSA) and (b) time points for 100: 20 (NP: BSA) BSA loading concentration, * is p < 
0.5, ** is p < 0.05, ANOVA/Tukey’s comparison (Mean±SD, n=3) 
Fig. 3 SEM pictures of PGA-co-PDL/L-Leu Nanocomposite Microparticles (a) 5 µm and (b) 
2 µm 
Fig. 4 Confocal microscopic image of spray-dried microparticles containing the fluorescent 
nanoparticles (red, labelled using nile red dye) adsorbed with FITC-BSA (green) (a) Split 
view and (b) Orthogonal view 
Fig. 5 In vitro release profiles for BSA adsorbed PGA-co-PDL/L-leu NCMPs in phosphate 
buffer saline, pH 7.4 (Mean±SD, n=3) 
Fig. 6 SDS-PAGE of Lane 1: molecular weight standards, broad range (Bio-Rad 
Laboratories, Hercules CA, USA), Lane 2, 3: BSA standards, Lane 4, 5, 6: Desorbed BSA 
from PGA-co-PDL/L-leu NCMPs after 24 h 
Fig. 7 CD spectra of (a) standard BSA (grey) and supernatant BSA (black) and (b) standard 
BSA (grey) and BSA released (black) 
Fig. 8 A549 & 16HBE14o- cell viability measured by MTT assay after 24 h exposure to 
PGA-co-PDL NCMPs (Mean±SD, n=3) 
Legends to Figures
Click here to download Figure: Legends to Figures.docx 
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